Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning. My name is Rob and I will be your conference ...

SE (ARGNF) reports robust product sales growth and a solid cash position, while navigating increased expenses and competitive ...

Discover how argenx's strong Q3 results and promising pipeline are driving growth, despite high valuation after share price ...

The company has laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...

Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Zai Lab (ZLAB) reported topline data from a Phase 3 study for KarXT in the treatment of schizophrenia, with plans to file for approval in China in early 2025. Read more here.

Ircam Amplify, a global leader in AI audio technology that is the commercial branch of the French audio research lab IRCAM-Centre Pompidou, has developed an AI Speech Detector tool to support ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...